UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 29, 2025

 

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

0-50956

20-0653570

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

6 Road 696, Dorado, Puerto Rico

 

00646

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (787) 278-2709 

 

 ___________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

 

 

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01. Other Events.

 

On January 29, 2025, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing that the Board of Directors approved a Special Dividend of $0.075 per share to shareholders. The dividend is payable on or about March 20, 2025 to shareholders of record at the close of business on February 28, 2025. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release, dated January 29, 2025.

104

 

Cover page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PHARMA-BIO SERV, INC.

 

 

 

 

 

Date: January 29, 2025

By:  

/s/ Pedro J. Lasanta

 

 

 

Pedro J. Lasanta  

 

 

 

Chief Financial Officer, Vice President Finance and Administration and Secretary

 

 

 

3

 

nullv3.24.4
Cover
Jan. 29, 2025
Cover [Abstract]  
Entity Registrant Name Pharma-Bio Serv, Inc.
Entity Central Index Key 0001304161
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jan. 29, 2025
Entity File Number 0-50956
Entity Incorporation State Country Code DE
Entity Tax Identification Number 20-0653570
Entity Address Address Line 1 6 Road 696
Entity Address City Or Town Dorado
Entity Address Postal Zip Code 00646
City Area Code 787
Local Phone Number 278-2709
Entity Address Country PR
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false

Pharma Bio Serv (QB) (USOTC:PBSV)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Pharma Bio Serv (QB).
Pharma Bio Serv (QB) (USOTC:PBSV)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Pharma Bio Serv (QB).